

Supplementary Online Content

Ghoneem A, Osborne MT, Abohashem S, et al. Association of socioeconomic status and infarct volume with functional outcome in patients with ischemic stroke. *JAMA Netw Open*. 2022;5(4):e229178. doi:10.1001/jamanetworkopen.2022.9178

eMethods 1. Area Deprivation Index

eMethods 2. Infarct Volume Measurement by MRI

eMethods 3. The Causative Classification System of Stroke (CCS)

eMethods 4. Assumptions of Linear Regression

eMethods 5. Mediation Analysis

eMethods 6. Income for Patients Who Underwent MRI (Included in the Study) and Those Who Did Not (Excluded)

eTable 1. Distribution of Different Stroke Locations Across Income Quintiles

eTable 2. Association Between SES Measures and Initial Stroke Severity Indices (Using Income in \$10 000 Increments, Infarct Volume in Cubic Centimeters, and NIHSS in Point Form)

eTable 3. Association Between Extremes of Median Income (First and Fifth Quintiles) and Initial Stroke Severity Indices After Excluding Patients With Minor Strokes (NIHSS Score ≤ 4)

eTable 4. Association Between SES Measures and Functional Outcome at 90 Days

eTable 5. Association Between SES Measures and Functional Outcome at 90 Days Adjusted for Stroke Location

eTable 6. Association Between SES Measures and Functional Outcome at 90 Days Using Ordinal Regression Model

eTable 7. Association Between Initial Stroke Severity Indices and Functional Outcome at 90 Days

eTable 8. Association Between SES Measures and Functional Outcome at 90 Days Within the Subset of Patients Who Did Not Receive Reperfusion Therapies

eTable 9. Mediation Analysis Models With Multivariable Adjustments

eTable 10. Association Between SES Measures and Initial Stroke Severity Indices (Within the Subgroup of Patients With LAA and CE Strokes)

eTable 11. Association Between SES Measures and Functional Outcome at 90 Days (Within the Subgroup of Patients With LAA and CE Strokes)

eFigure 1. Distribution of Infarct Volume by Median Household Income

eFigure 2. Association Between Different SES Measures (Income and ADI) and Study End Points

eFigure 3. Single-Mediator Mediation Analyses

eFigure 4. A Serial 2-Mediator Mediation Analysis

eFigure 5. Association Between Different SES Measures (Income and ADI) vs Study End Points Within the Subgroup of Patients With LAA and CE Strokes

eReferences

This supplementary material has been provided by the authors to give readers additional information about their work.

© 2022 Ghoneem A et al. *JAMA Network Open*.

eMethods 1. Area Deprivation Index

ADI combines 17 weighted census indicators (e.g., measures of education, employment, housing quality, poverty).¹ ADI was collected for all Massachusetts residents in the study population. Each patient address was geo-linked to their Area Deprivation Index (ADI) neighborhood ranking using the mapping function freely available through the Neighborhood Atlas (<https://www.neighborhoodatlas.medicine.wisc.edu/>).² ADI data is available in rank form as deciles within each state with the first decile being least disadvantaged, and the tenth decile being the most disadvantaged.

eMethods 2. Infarct Volume Measurement by MRI

We used a commercially available image display and analysis program (MRICron). Clinically relevant regions characterized by increased signal intensity on DWI and decreased intensity on the apparent diffusion coefficient maps were classified as acute infarct. Examiners were provided with a brief clinical history and neurological examination findings for each patient. The outlining technique was manual. Lesion volumes were automatically produced by the software based on the slice thickness and overall outlined lesion area. In patients with multiple infarcts, the sum of all infarct volumes was calculated. This technique has excellent interrater reliability with intraclass correlation coefficient ranging between 0.93 and 0.99.³

eMethods 3. The Causative Classification System of Stroke (CCS)

The Causative Classification System of Stroke (CCS) is a computerized, evidence-based algorithm that was developed in 2005 and has been used by several stroke centers since then.⁴⁻⁶ It classifies stroke etiology with high inter-rater agreement rates ranging from 80% to 95%.⁷ It was validated against the assessment of 20 expert neurologists with a κ value for causative classification of 0.80 (95% confidence interval [CI] 0.78–0.81) for the 5-subtype CCS.⁸ The primary reference was added to the manuscript.

eMethods 4. Assumptions of Linear Regression

To ensure that there was no multicollinearity, a Pearson correlation coefficient was calculated to examine the relationship between predictors. All predictors provided coefficient values closer to ($r=0$) rather than ($r=0.7$ or $r=-0.7$), tolerance values above 0.1 and variance inflation factor below 10, which in turn suggested that the assumption of multicollinearity wasn't violated. A Durbin-Watson statistic was calculated to assess the assumption that the values of the residuals are independent, which suggested that this assumption wasn't violated (Durbin-Watson=1.807). Cook's Distance values were calculated to ensure that no influential cases were biasing the model. All values were below 1 (maximum Cook's Distance value =0.049), suggesting that no cases were biasing the model.

eMethods 5. Mediation Analysis

Mediation analysis was employed using the SPSS PROCESS macro to evaluate mechanisms underlying the association between SES and long-term disability. The analysis uses an ordinary least squares or logistic regression-based path structure to

estimate direct and indirect effects and confidence intervals (Cis) based upon 5,000 bias-corrected bootstrap samples.^{9,10} CIs for multi-step indirect pathways assessed using bootstrapping are frequently asymmetric, which hinders the ability to apply a parametric asymptotic distribution to quantify P values. Accordingly, 95% CIs that do not cross zero are deemed significant with $P < 0.05$.

eMethods 6. Income for Patients Who Underwent MRI (Included in the Study) and Those Who Did Not (Excluded)

Out of 1474 consecutive patients enrolled in our study, 218 patients did not undergo MRI and 48 patients were excluded for technical issues with their scans, yielding a total of 266 patients. Of this group, only 245 of those patients had available income data. The mean (SD) income of these patients was \$75463.6 (\$25158.4) vs. \$75937.1 (\$26653.8) for the 1098 patients included in the study ($P=0.98$).

eTable 1. Distribution of Different Stroke Locations Across Income Quintiles

Characteristic, N (%)	Complete Population	Income quintiles					<i>P</i> ^b
		First (N= 203)	Second (N=231)	Third (N=219)	Fourth (N=219)	Fifth (N=218)	
Stroke Location: Vascular territory (N=1090)							
ICA	53 (4.9)	15 (28.3)	10 (18.9)	15 (28.3)	10 (18.9)	3 (5.7)	0.17
MCA	583 (53.5)	105 (18.0)	116 (19.9)	114 (19.6)	122 (20.9)	126 (21.6)	
ACA	13 (1.2)	4 (30.8)	2 (15.4)	4 (30.8)	2 (15.4)	1 (7.7)	
PCA	89 (8.2)	16 (18.0)	18 (20.2)	17 (19.1)	21 (23.6)	17 (19.1)	
Cerebellar	46 (4.2)	11 (23.9)	7 (15.2)	10 (21.7)	3 (6.5)	15 (32.6)	
Brainstem	73 (6.7)	14 (19.2)	19 (26.0)	11 (15.1)	13 (17.8)	16 (21.9)	
Multiple	233 (21.4)	38 (16.3)	59 (25.3)	48 (20.6)	48 (20.6)	40 (17.2)	
Stroke Location: anterior, posterior or both (N=1089)							
Anterior	734 (67.4)	137 (18.7)	152 (20.7)	152 (20.7)	150 (20.4)	143 (19.5)	
Posterior	258 (23.7)	50 (19.4)	55 (21.3)	46 (17.8)	51 (19.8)	56 (21.7)	
Both	97 (8.9)	16 (16.5)	24 (24.7)	21 (21.6)	18 (18.6)	18 (18.6)	
Stroke Location: laterality (N=1090)							
Left	485 (44.5)	99 (20.4)	93 (19.2)	93 (19.2)	104 (21.4)	96 (19.8)	0.628
Right	414 (38)	74 (17.9)	90 (21.7)	87 (21)	76 (18.4)	87 (21)	
Both	191 (17.5)	30 (15.7)	48 (25.1)	39 (20.4)	39 (20.4)	35 (18.3)	

eTable 2. Association Between SES Measures and Initial Stroke Severity Indices (Using Income in \$10 000 Increments, Infarct Volume in Cubic Centimeters, and NIHSS in Point Form)

Models with covariables	Median income and initial stroke severity indices (N=1098)				ADI and initial stroke severity indices (N= 943)			
	Infarct Volume (cc)		NIHSS		Infarct Volume (cc)		NIHSS	
	β (95% CI)	<i>p</i>	β (95% CI)	<i>p</i>	β (95% CI)	<i>p</i>	β (95% CI)	<i>p</i>
NONE (unadjusted)	-1.700 (-3.308, -0.362)	0.01	-0.299 (-0.457, -0.141)	<0.001	1.726 (0.276, 3.176)	0.02	0.386 (0.215, 0.556)	<0.001
Age, sex, and race	-1.700 (-3.308, -0.362)	0.01	-0.273 (-0.431, -0.115)	0.001	1.726 (0.276, 3.176)	0.02	0.412 (0.244, 0.581)	<0.001
Stroke risk factors^a	-1.665 (-2.878, -0.451)	0.007	-0.297 (-0.451, -0.143)	<0.001	1.700 (0.410, 2.991)	0.01	0.391 (0.225, 0.557)	<0.001
Atherosclerotic risk factors^b	-1.545 (-2.776, -0.314)	0.01	-0.294 (-0.450, -0.137)	<0.001	1.735 (0.432, 3.039)	0.009	0.405 (0.236, 0.574)	<0.001
Pre-stroke medications^c	-1.665 (-3.043, -0.356)	0.013	-0.298 (-0.456, -0.140)	<0.001	1.704 (0.246, 3.162)	0.02	0.386 (0.215, 0.558)	<0.001
Time from symptom onset to admission	-1.663 (-3.162, -0.164)	0.03	-0.292 (-0.463, -0.120)	<0.001	1.737 (0.081, 3.392)	0.04	0.381 (0.196, 0.566)	<0.001
Health Insurance	-1.701 (-3.040, -0.362)	0.01	-0.298 (-0.456, -0.141)	<0.001	1.726 (0.275, 3.176)	0.02	0.385 (0.215, 0.555)	<0.001

All covariables combined	-1.516 (-2.850, -0.181)	0.03	-0.258 (-0.425, -0.091)	0.003	1.605 (0.169, 3.041)	0.03	0.347 (0.164, 0.530)	<0.001
---------------------------------	----------------------------	------	----------------------------	-------	-------------------------	------	-------------------------	--------

a: Age, sex, smoking, diabetes, hypertension, dyslipidemia, history of stroke or TIA, atrial fibrillation, coronary artery disease, and congestive heart failure.

B: Age, sex, smoking, diabetes, hypertension, and dyslipidemia.

C: Antiplatelets, statins, and anticoagulants.

NIHSS: National Institute of Health Stroke Scale, ADI: Area Deprivation Index

eTable 3. Association Between Extremes of Median Income (First and Fifth Quintiles) and Initial Stroke Severity Indices After Excluding Patients With Minor Strokes (NIHSS Score ≤ 4)

Model covariables	Median income and initial stroke severity indices (N= 488)			
	Infarct Volume		NIHSS	
	Standardized β (95% CI)	p	Standardized β (95% CI)	p
NONE (unadjusted)	-0.164 (-0.234, -0.095)	<0.001	-0.285 (-0.338, -0.231)	<0.001
Age, sex, and race	-0.164 (-0.234, -0.095)	<0.001	-0.285 (-0.338, -0.231)	<0.001
Stroke risk factors^a	-0.127 (-0.182, -0.073)	<0.001	-0.257 (-0.310, -0.204)	<0.001
Atherosclerotic risk factors^b	-0.127 (-0.182, -0.073)	<0.001	-0.263 (-0.318, -0.209)	<0.001
Pre-stroke medications^c	-0.162 (-0.231, -0.092)	<0.001	-0.284 (-0.338, -0.230)	<0.001
Time from symptom onset to admission	-0.155 (-0.234, -0.076)	<0.001	-0.265 (-0.323, -0.207)	<0.001
Health Insurance	-0.164 (-0.233, -0.095)	<0.001	-0.284 (-0.337, -0.231)	<0.001
All covariables combined	-0.100 (-0.158, -0.041)	0.001	-0.225 (-0.281, -0.170)	<0.001

a: Age, sex, smoking, diabetes, hypertension, dyslipidemia, history of stroke or TIA, atrial fibrillation, coronary artery disease, and congestive heart failure.

b: Age, sex, smoking, diabetes, hypertension, and dyslipidemia.

c: Antiplatelets, statins, and anticoagulants.

NIHSS: National Institute of Health Stroke Scale

eTable 4. Association Between SES Measures and Functional Outcome at 90 Days

Models with covariables	Median income and mRS at 90 days (N=1015)		ADI and mRS at 90 days (N=874)	
	Standardized β	<i>p</i>	Standardized β	<i>p</i>
	(95% CI)		(95% CI)	
NONE (unadjusted)	-0.106 (-0.167, -0.045)	0.001	0.039 (0.014, 0.064)	0.002
Age, sex, and race	-0.1 (-0.159, -0.042)		0.047 (0.023, 0.071)	
Stroke risk factors ^a	-0.092 (-0.149, -0.035)	0.001	0.038 (0.015, 0.062)	0.001
Atherosclerotic risk factors ^b	-0.092 (-0.150, -0.034)		0.04 (0.016, 0.064)	
Pre-stroke medications ^c	-0.102 (-0.164, -0.041)	0.001	0.038 (0.013, 0.063)	0.003
Time from symptom onset to admission	-0.099 (-0.167, -0.031)		0.004	
Baseline mRS	-0.099 (-0.158, -0.040)	0.001	0.039 (0.014, 0.063)	0.002
Insurance	-0.106 (-0.167, -0.045)		0.001	
Combined pre-admission variables ^d	-0.077 (-0.139, -0.015)	0.01	0.036 (0.011, 0.061)	0.005
Reperfusion therapies ^e	-0.080 (-0.147, -0.012)		0.02	
Discharge medications ^f	-0.106 (-0.165, -0.047)	<0.001	0.040 (0.016, 0.064)	<0.001
Combined post-admission variables ^g	-0.069 (-0.133, -0.006)		0.03	

a: Age, sex, smoking, diabetes, hypertension, dyslipidemia, history of stroke or TIA, atrial fibrillation, coronary artery disease, and congestive heart failure.

b: Age, sex, smoking, diabetes, hypertension, and dyslipidemia.

c: Antiplatelets, statins, and anticoagulants.

d: Age, sex, race, stroke risk factors, pre-stroke medications, time from symptom onset to admission, baseline mRS, and insurance.

e: Intravenous/intraarterial thrombolytics and stents.

f: Antiplatelets, statins, antihypertensives, anticoagulants, beta blockers, and ACEI's/ARB's.

g: Reperfusion therapies, discharge medications, and insurance.

NIHSS: National Institute of Health Stroke Scale, mRS: modified Rankin Scale

ADI: Area Deprivation Index

eTable 5. Association Between SES Measures and Functional Outcome at 90 Days Adjusted for Stroke Location

Models with covariables	Median income and mRS at 90 days (N=1007)		ADI vs mRS at 90 days (N=867)	
	Standardized β	<i>p</i>	Standardized β	<i>p</i>
	(95% CI)		(95% CI)	
Location: vascular territory (ICA, MCA, ACA, PCA, Cerebellar, Brain stem, multiple)	-0.111 (-0.172, -0.050)	<0.001	0.039 (0.014, 0.064)	0.002
Location: anterior, posterior or both	-0.111 (-0.172, -0.049)	<0.001	0.039 (0.014, 0.064)	0.002
Location: left, right or both	-0.115 (-0.175, -0.054)	<0.001	0.043 (0.018, 0.068)	<0.001

ICA: Internal Carotid Artery
MCA: Middle Cerebral Artery
ACA: Anterior Cerebral Artery
PCA: Posterior Cerebral Artery

eTable 6. Association Between SES Measures and Functional Outcome at 90 Days Using Ordinal Regression Model

Models with covariables	Ordinal Regression Analysis			
	Median income and mRS at 90 days (N=1015)		ADI and mRS at 90 days (N=874)	
	Standardized β	<i>p</i>	Standardized β	<i>p</i>
	(95% CI)		(95% CI)	
NONE (unadjusted)	-0.194 (-0.303, -0.084)	0.001	0.074 (0.029, 0.118)	0.001
Age, sex, and race	-0.202 (-0.313, -0.091)	<0.001	0.083 (0.037, 0.129)	<0.001
Stroke risk factors ^a	-0.192 (-0.304, -0.079)	0.001	0.074 (0.027, 0.121)	0.002
Atherosclerotic risk factors ^b	-0.183 (-0.295, -0.072)	0.001	0.080 (0.035, 0.126)	0.001
Pre-stroke medications ^c	-0.192 (-0.301, -0.082)	0.001	0.072 (0.027, 0.117)	0.002
Time from symptom onset to admission	-0.177 (-0.298, -0.055)	0.004	0.069 (0.019, 0.119)	0.007
Baseline mRS	-0.193 (-0.303, -0.083)	0.001	0.083 (0.038, 0.127)	<0.001
Insurance	-0.195 (-0.304, -0.086)	<0.001	0.074 (0.030, 0.119)	0.001
Combined pre-admission variables ^d	-0.165 (-0.292, -0.038)	0.011	0.075 (0.022, 0.128)	0.006
Reperfusion therapies ^e	-0.147 (-0.269, -0.025)	0.02	0.073 (0.023, 0.124)	0.004
Discharge medications ^f	-0.200 (-0.311, -0.090)	<0.001	0.081 (0.036, 0.126)	<0.001
Combined post-admission variables ^g	-0.160 (-0.284, -0.036)	0.01	0.074 (0.023, 0.126)	0.004

a: Age, sex, smoking, diabetes, hypertension, dyslipidemia, history of stroke or TIA, atrial fibrillation, coronary artery disease, and congestive heart failure.

b: Age, sex, smoking, diabetes, hypertension, and dyslipidemia.

c: Antiplatelets, statins, and anticoagulants.

d: Age, sex, race, stroke risk factors, pre-stroke medications, time from symptom onset to admission, baseline mRS, and insurance.

e: Intravenous/intraarterial thrombolytics and stents.

f: Antiplatelets, statins, antihypertensives, anticoagulants, beta blockers, and ACEI's/ARB's.

g: Reperfusion therapies, discharge medications, and insurance.

NIHSS: National Institute of Health Stroke Scale, mRS: modified Rankin Scale

ADI: Area Deprivation Index

eTable 7. Association Between Initial Stroke Severity Indices and Functional Outcome at 90 Days

Models with covariables	Initial stroke severity indices and mRS at 90 days (N=1015)			
	Infarct Volume		NIHSS	
	Standardized β (95% CI)	<i>p</i>	Standardized β (95% CI)	<i>p</i>
NONE (unadjusted)	0.412 (0.357, 0.467)	<0.001	0.607 (0.559, 0.655)	<0.001
Age, sex, and race	0.404 (0.352, 0.456)	<0.001	0.581 (0.534, 0.627)	<0.001
Stroke risk factors^a	0.450 (0.395, 0.506)	<0.001	0.571 (0.525, 0.617)	<0.001
Atherosclerotic risk factors^b	0.464 (0.408, 0.519)	<0.001	0.574 (0.528, 0.621)	<0.001
Pre-stroke medications^c	0.412 (0.357, 0.466)	<0.001	0.606 (0.558, 0.654)	<0.001
Time from symptom onset to admission	0.396 (0.335, 0.457)	<0.001	0.610 (0.555, 0.666)	<0.001
Baseline mRS	0.466 (0.409, 0.524)	<0.001	0.587 (0.540, 0.634)	<0.001
Insurance	0.411 (0.357, 0.466)	<0.001	0.608 (0.559, 0.656)	<0.001
Combined pre-admission variables^d	0.419 (0.357, 0.480)	<0.001	0.538 (0.485, 0.591)	<0.001
Reperfusion therapies^e	0.463 (0.398, 0.528)	<0.001	0.643 (0.585, 0.700)	<0.001
Discharge medications^f	0.379 (0.319, 0.439)	<0.001	0.546 (0.496, 0.596)	<0.001
Combined post-admission variables^g	0.401 (0.334, 0.467)	<0.001	0.594 (0.536, 0.653)	<0.001

a: Age, sex, smoking, diabetes, hypertension, dyslipidemia, history of stroke or TIA, atrial fibrillation, coronary artery disease, and congestive heart failure.

b: Age, sex, smoking, diabetes, hypertension, and dyslipidemia.

c: Antiplatelets, statins, and anticoagulants.

d: Age, sex, race, stroke risk factors, pre-stroke medications, time from symptom onset to admission, baseline mRS, and insurance.

e: Intravenous/intraarterial thrombolytics and stents.

f: Antiplatelets, statins, antihypertensives, anticoagulants, beta blockers, and ACEI's/ARB's.

g: Reperfusion therapies, discharge medications, and insurance.

NIHSS: National Institute of Health Stroke Scale, mRS: modified Rankin Scale

eTable 8. Association Between SES Measures and Functional Outcome at 90 Days Within the Subset of Patients Who Did Not Receive Reperfusion Therapies

Models with covariables	Median Income and mRS at 90 days (N=799)		ADI and mRS at 90 days (N=699)	
	Standardized β (95% CI)	<i>p</i>	Standardized β (95% CI)	<i>p</i>
NONE (unadjusted)	-0.096 (-0.162, -0.030)	0.005	0.038 (0.011, 0.065)	0.007
Age, sex, and race	-0.089 (-0.153, -0.025)	0.007	0.043 (0.017, 0.069)	0.001
Stroke risk factors^a	-0.076 (-0.138, -0.015)	0.02	0.033 (0.008, 0.059)	0.01
Atherosclerotic risk factors^b	-0.074 (-0.137, -0.011)	0.02	0.035 (0.009, 0.061)	0.008
Pre-stroke medications^c	-0.094 (-0.160, -0.027)	0.005	0.037 (0.009, 0.064)	0.010
Time from symptom onset to admission	-0.093 (-0.167, -0.019)	0.01	0.036 (0.006, 0.066)	0.02
Baseline mRS	-0.087 (-0.151, 0.023)	0.008	0.038 (0.011, 0.064)	0.005
Insurance	-0.097 (-0.163, -0.031)	0.004	0.038 (0.010, 0.065)	0.007
Discharge medications^d	-0.088 (-0.151, -0.025)	0.006	0.036 (0.011, 0.062)	0.006

a: Age, sex, smoking, diabetes, hypertension, dyslipidemia, history of stroke or TIA, atrial fibrillation, coronary artery disease, and congestive heart failure.

b: Age, sex, smoking, diabetes, hypertension, dyslipidemia.

c: Antiplatelets, statins, and anticoagulants.

d: Antiplatelets, statins, antihypertensives, anticoagulants, beta blockers and ACEI's/ARB's.

ADI: Area Deprivation Index, mRS: modified Rankin Scale

eTable 9. Mediation Analysis Models With Multivariable Adjustments

Model covariables	Indirect paths	Standardized β (95% CI)	p	% of total effect of SES on functional outcome at 90 days
NONE (unadjusted) (n=993)	Income → Infarct vol → mRS	-0.0071 (-0.0143, -0.0014)	<0.05	7
	Income → NIHSS → mRS	-0.0396 (-0.0660, -0.0131)	<0.05	41
	Income → Infarct vol → NIHSS → mRS	-0.0197 (-0.0351, -0.0045)	<0.05	21
	Combined indirect paths	-0.0663 (-0.1017, -0.0314)	<0.05	69
Age and sex (n=993)	Income → Infarct vol → mRS	-0.0083 (-0.0157, -0.0018)	<0.05	8
	Income → NIHSS → mRS	-0.0364 (-0.0608, -0.0116)	<0.05	37
	Income → Infarct vol → NIHSS → mRS	-0.0184 (-0.0321, -0.0039)	<0.05	19
	Combined indirect paths	-0.0631 (-0.0955, -0.0288)	<0.05	64
Age, sex, and race (n=993)	Income → Infarct vol → mRS	-0.0086 (-0.0162, -0.0016)	<0.05	9
	Income → NIHSS → mRS	-0.0320 (-0.0557, -0.0088)	<0.05	35
	Income → Infarct vol → NIHSS → mRS	-0.0186 (-0.0324, -0.0033)	<0.05	20
	Combined indirect paths	-0.0591 (-0.0925, -0.0249)	<0.05	64
Stroke risk factors^a (n=991)	Income → Infarct vol → mRS	0.0100 (-0.0194, -0.0018)	<0.05	13

	Income → NIHSS → mRS	-0.0340 (-0.0569, -0.0121)	<0.05	41
	Income → Infarct vol → NIHSS → mRS	-0.0170 (-0.0313, -0.0031)	<0.05	20
	Combined indirect paths	-0.0610 (-0.0948, -0.0284)	<0.05	74
Atherosclerotic risk factors^b (n=991)	Income → Infarct vol → mRS	0.0090 (-0.0181, -0.0011)	<0.05	11
	Income → NIHSS → mRS	-0.0332 (-0.0564, -0.0103)	<0.05	40
	Income → Infarct vol → NIHSS → mRS	-0.0167 (-0.0314, -0.0020)	<0.05	20
	Combined indirect paths	-0.0590 (-0.0923, -0.0242)	<0.05	71
Model covariables	Indirect paths	β (95% CI)	p	% of total effect of Income on functional outcome at 90 days
Pre-stroke medications^c (n=984)	Income → Infarct vol → mRS	0.0070 (-0.0140, -0.0013)	<0.05	8
	Income → NIHSS → mRS	-0.0412 (-0.0666, -0.0155)	<0.05	44
	Income → Infarct vol → NIHSS → mRS	-0.0197 (-0.0346, -0.0045)	<0.05	21
	Combined indirect paths	-0.0679 (-0.1021, -0.0327)	<0.05	73
Time from symptom onset to admission (n=792)	Income → Infarct vol → mRS	0.0068 (-0.0146, -0.0008)	<0.05	8
	Income → NIHSS → mRS	-0.0420 (-0.0702, -0.0127)	<0.05	47

	Income → Infarct vol → NIHSS → mRS	-0.0199 (-0.0364, - 0.0022)	<0.05	22
	Combined indirect paths	-0.0687 (-0.1064, - 0.0288)	<0.05	77
Baseline mRS (n=991)	Income → Infarct vol → mRS	0.0080 (-0.0160, - 0.0014)	<0.05	9
	Income → NIHSS → mRS	-0.0353 (-0.598, - 0.0116)	<0.05	40
	Income → Infarct vol → NIHSS → mRS	-0.0183 (-0.0332, - 0.0035)	<0.05	21
	Combined indirect paths	-0.0617 (-0.0945, - 0.0274)	<0.05	70
Insurance (n=993)	Income → Infarct vol → mRS	0.0071 (-0.0142, - 0.0012)	<0.05	7
	Income → NIHSS → mRS	-0.0395 (-0.0656, - 0.0143)	<0.05	41
	Income → Infarct vol → NIHSS → mRS	-0.0197 (-0.0349, - 0.0039)	<0.05	21
	Combined indirect paths	-0.0662 (-0.1011, - 0.0312)	<0.05	69
Discharge medications^d (n=990)	Income → Infarct vol → mRS	0.0050 (-0.0113, - 0.0005)	<0.05	5
	Income → NIHSS → mRS	-0.0383 (-0.0631, - 0.0141)	<0.05	41
	Income → Infarct vol → NIHSS → mRS	-0.0173 (-0.0330, - 0.0029)	<0.05	19
	Combined indirect paths	-0.0606 (-0.0927, - 0.0285)	<0.05	65

a: Age, sex, smoking, diabetes, hypertension, dyslipidemia, history of stroke or TIA, atrial fibrillation, coronary artery disease, and congestive heart failure.

b: Age, sex, smoking, diabetes, hypertension, and dyslipidemia.

c: Antiplatelets, statins, and anticoagulants.

d: Antiplatelets, statins, antihypertensives, anticoagulants, beta blockers, and ACEI's/ARB's.

SES: socioeconomic status, NIHSS: National Institutes of Health Stroke Scale, mRS: modified Rankin Scale

eTable 10. Association Between SES Measures and Initial Stroke Severity Indices (Within the Subgroup of Patients With LAA and CE Strokes)

Models with covariables	Median income and initial stroke severity indices (N= 727)				ADI and initial stroke severity indices (N=621)			
	Infarct Volume		NIHSS		Infarct Volume		NIHSS	
	Standardized β (95% CI)	<i>p</i>	Standardized β (95% CI)	<i>p</i>	Standardized β (95% CI)	<i>p</i>	Standardized β (95% CI)	<i>p</i>
NONE (unadjusted)	-0.098 (-0.174, -0.022)	0.01	-0.157 (-0.232, -0.082)	<0.001	0.036 (0.004, 0.068)	0.03	0.078 (0.047, 0.109)	<0.001
Age, sex, and race	-0.097 (-0.173, -0.021)	0.01	-0.143 (-0.218, -0.068)	<0.001	0.036 (0.004, 0.068)	0.03	0.079 (0.049, 0.110)	<0.001
Stroke risk factors ^a	-0.089 (-0.157, -0.022)	0.009	-0.156 (-0.230, -0.083)	<0.001	0.038 (0.011, 0.065)	0.006	0.075 (0.045, 0.106)	<0.001
Atherosclerotic risk factors ^b	-0.081 (-0.148, -0.013)	0.02	-0.153 (-0.227, -0.078)	<0.001	0.036 (0.009, 0.064)	0.01	0.080 (0.050, 0.111)	<0.001
Pre-stroke medications ^c	-0.097 (-0.173, -0.021)	0.01	-0.155 (-0.230, -0.079)	<0.001	0.035 (0.003, 0.067)	0.03	0.078 (0.047, 0.110)	<0.001
Time from symptom onset to admission	-0.099 (-0.185, -0.014)	0.02	-0.143 (-0.232, -0.073)	<0.001	0.038 (0.002, 0.074)	0.04	0.075 (0.042, 0.108)	<0.001
Insurance	-0.098 (-0.174, -0.022)	0.01	-0.149 (-0.232, -0.082)	<0.001	0.036 (0.004, 0.068)	0.03	0.075 (0.042, 0.108)	<0.001

All covariables	-0.078 (-0.151, - 0.004)	0.04	-0.129 (-0.206, - 0.051)	0.001	0.038 (0.008, 0.067)	0.01	0.074 (0.042, 0.106)	<0.001
------------------------	--------------------------------	------	--------------------------------	-------	-------------------------	------	-------------------------	--------

a: Age, sex, smoking, diabetes, hypertension, dyslipidemia, history of stroke or TIA, atrial fibrillation, coronary artery disease, and congestive heart failure.

b: Age, sex, smoking, diabetes, hypertension, and dyslipidemia.

c: Antiplatelets, statins, and anticoagulants.

LAA: large artery atherosclerosis, CE: cardioaortic embolic, NIHSS: National Institute of Health Stroke Scale

ADI: Area Deprivation Index

eTable 11. Association Between SES Measures and Functional Outcome at 90 Days (Within the Subgroup of Patients With LAA and CE Strokes)

Models with covariables	Median income and mRS at 90 days (N=667)		ADI and mRS at 90 days (N=570)	
	Standardized β (95% CI)	<i>p</i>	Standardized β (95% CI)	<i>p</i>
NONE (unadjusted)	-0.139 (-0.214, -0.063)	<0.001	0.049 (0.017, 0.081)	<0.001
Age, sex, and race	-0.136 (-0.206, -0.065)	<0.001	0.054 (0.024, 0.084)	<0.001
Stroke risk factors ^a	-0.115 (-0.184, -0.045)	0.001	0.042 (0.013, 0.071)	0.005
Atherosclerotic risk factors ^b	-0.114 (-0.185, -0.044)	0.001	0.045 (0.015, 0.075)	0.003
Pre-stroke medications ^c	-0.137 (-0.212, -0.061)	<0.001	0.048 (0.016, 0.080)	0.003
Time from symptom onset to admission	-0.136 (-0.220, -0.053)	0.001	0.048 (0.013, 0.084)	0.007
Baseline mRS	-0.122 (-0.195, -0.050)	0.001	0.045 (0.014, 0.076)	0.004
Insurance	-0.139 (-0.214, -0.064)	<0.001	0.049 (0.017, 0.081)	0.003
Combined pre-admission variables ^d	-0.104 (-0.178, -0.031)	0.005	0.037 (0.006, 0.068)	0.02
Reperfusion therapies ^e	-0.114 (-0.197, -0.032)	0.007	0.055 (0.021, 0.090)	0.002
Discharge medications ^f	-0.131 (-0.201, -0.062)	<0.001	0.049 (0.020, 0.078)	0.001
Combined post-admission variables ^g	-0.109 (-0.185, -0.033)	0.005	0.048 (0.016, 0.079)	0.003

a: Age, sex, smoking, diabetes, hypertension, dyslipidemia, history of stroke or TIA, atrial fibrillation, coronary artery disease, and congestive heart failure.

b: Age, sex, smoking, diabetes, hypertension, and dyslipidemia.

c: Antiplatelets, statins, and anticoagulants.

d: Age, sex, race, stroke risk factors, pre-stroke medications, time from symptom onset to admission, baseline mRS, and insurance


e: Intravenous/intraarterial thrombolytics and stents.

f: Antiplatelets, statins, antihypertensives, anticoagulants, beta blockers, and ACEI's/ARB's.

g: Reperfusion therapies, discharge medications, and insurance.


NIHSS: National Institute of Health Stroke Scale, mRS: modified Rankin Scale, ADI: Area Deprivation Index

eFigure 1. Distribution of Infarct Volume by Median Household Income



P value corresponds to the correlation coefficient -0.075

eFigure 2. Association Between Different SES Measures (Income and ADI) and Study End Points




A-C: Median income quintiles and: A) infarct size (infarct volume on MRI), B) clinical stroke severity on admission (NIHSS), C) functional outcome at 90 days (mRS).

D-F: ADI quintiles versus: D) infarct size (infarct volume on MRI), E) clinical stroke severity on admission (NIHSS), F) functional outcome at 90 days (mRS).


Error bars=1 standard error. NIHSS: National Institute of Health Stroke Scale, mRS: modified Rankin Scale. ADI: Area Deprivation Index.

eFigure 3. Single-Mediator Mediation Analyses

A




B



Single-mediator mediation analyses showing that infarct volume is a significant mediator of the relationship between SES (A: median income, B: ADI) and initial clinical stroke severity. The indirect pathway of lower income or higher ADI leading to larger strokes leading to more clinically severe strokes on admission was statistically significant in models adjusted for age and sex. NIHSS: National Institute of Health Stroke Scale, ADI: Area Deprivation Index.

eFigure 4. A Serial 2-Mediator Mediation Analysis



Indirect Path 1: ADI Quintiles → Infarction Volume → Functional outcome at 90-days
 β [95%CI] = 0.0070 (0.0003, 0.0162), $p < 0.05$
 Accounting for 8% of total effect

Indirect Path 2: ADI Quintiles → Infarction Volume → Admission NIHSS → Functional outcome at 90-days
 β [95%CI] = 0.0144 (0.0006, 0.0303), $p < 0.05$
 Accounting for 16 % of total effect


Indirect Path 3: ADI Quintiles → Admission NIHSS → Functional outcome at 90-days
 β [95%CI] = 0.0379 (0.0148, 0.0621), $p < 0.05$
 Accounting for 43% of total effect


Combined Indirect Paths (Indirect Paths 1, 2 and 3):
 β [95%CI] = 0.0593 (0.0279, 0.0923), $p < 0.05$
 Accounting for 67% of total effect

This model shows that initial stroke severity indices were significant mediators of the relation between ADI and functional outcome. Within this model, all indirect pathways involving both infarct volume or admission NIHSS (whether alone or in series) were statistically significant (adjusted for age and sex). Note that the direct effect was not statistically significant (i.e., excluding initial indices negated the association between SES and functional outcome).

ADI: Area Deprivation Index, NIHSS: National Institute of Health Stroke Sca

eFigure 5. Association Between Different SES Measures (Income and ADI) vs Study End Points Within the Subgroup of Patients With LAA and CE Strokes





A-C: Median income quintiles and: A) infarct size (infarct volume on MRI), B) clinical stroke severity on admission (NIHSS), C) functional outcome at 90 days (mRS).

D-F: ADI quintiles versus: D) infarct size (infarct volume on MRI), E) clinical stroke severity on admission (NIHSS), F) functional outcome at 90 days (mRS).

Error bars=1 standard error. NIHSS: National Institute of Health Stroke Scale, mRS: modified Rankin Scale. ADI: Area Deprivation Index.

eReferences

1. Singh GK. Area deprivation and widening inequalities in US mortality, 1969-1998. *Am J Public Health*. 2003;93(7):1137-1143.
2. Kind AJH, Buckingham WR. Making Neighborhood-Disadvantage Metrics Accessible - The Neighborhood Atlas. *The New England journal of medicine*. 2018;378(26):2456-2458.
3. Ay H, Arsava EM, Vangel M, et al. Interexaminer Difference in Infarct Volume Measurements on MRI. *Stroke*. 2008;39(4):1171-1176.
4. Ay H, Furie KL, Singhal A, Smith WS, Sorensen AG, Koroshetz WJ. An evidence-based causative classification system for acute ischemic stroke. *Annals of neurology*. 2005;58(5):688-697.
5. Ay H, Benner T, Arsava EM, et al. A computerized algorithm for etiologic classification of ischemic stroke: the Causative Classification of Stroke System. *Stroke*. 2007;38(11):2979-2984.
6. Arsava EM, Helenius J, Avery R, et al. Assessment of the Predictive Validity of Etiologic Stroke Classification. *JAMA neurology*. 2017;74(4):419-426.
7. Ay H, Arsava EM, Andsberg G, et al. Pathogenic ischemic stroke phenotypes in the NINDS-stroke genetics network. *Stroke*. 2014;45(12):3589-3596.
8. Arsava EM, Ballabio E, Benner T, et al. The Causative Classification of Stroke system: an international reliability and optimization study. *Neurology*. 2010;75(14):1277-1284.
9. Tawakol A, Ishai A, Takx RAP, et al. Relation between resting amygdalar activity and cardiovascular events: a longitudinal and cohort study. *The Lancet*. 2017;389(10071):834-845.
10. Introduction to Mediation, Modera- tion, and Conditional Process Analysis: A Regression-Based Approach [press release]. New York: Guilford Press2013.